An observational study in Infant, Premature, Diseases, Bronchopulmonary Dysplasia and Respiratory Distress Syndrome, sponsored by Winston Manimtim. Completed at 1 site in United States. Per ClinicalTrials.gov, last updated 2026-11-13.
Sponsored by Winston Manimtim · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 147 studies in Bronchopulmonary Dysplasia with a site in United States — 29 open to participants now, 36 under way, 1 of them phase 3. Bronchopulmonary Dysplasia · United States.
Among the 147 studies in Bronchopulmonary Dysplasia with a site in United States, this one is the 24th largest by enrollment of the 30 observational ones that give a count, is one of 10 that started in 2019, is one of 30 observational ones, and was the 100th registered.
363 studies on the registry are indexed under Bronchopulmonary Dysplasia; 85 are open to participants now.
Browse Bronchopulmonary Dysplasia studies →29 of the 147 studies in Bronchopulmonary Dysplasia with a site in United States are open now. Recruiting first, the newest first:
NICHD Neonatal Research Network · Sites in United States
Ages up to 31 wk
University of Alabama at Birmingham · Sites in United States
Ages 7 days–30 days
University of Alabama at Birmingham · Sites in United States
Ages 1 mo–5 mo · Healthy volunteers
University of Alabama at Birmingham · Sites in United States
Ages 1 days–3 days
Augusta University · Sites in United States
Ages 25 wk–34 wk
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 57 Bronchopulmonary Dysplasia studies recruiting now, 6 (11%) set no upper age limit and 50 (88%) stop at 75 or younger; 55 take children under 18; 11 take healthy volunteers.
This study: all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
147 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 25 · Phase 2 36 · Phase 3 20 · Phase 4 7
First in 1991; this study’s year is marked. 10 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 44 is below the median of 150 across 100 observational studies indexed under Bronchopulmonary Dysplasia.
Median enrollment 50 across the 117 interventional studies, 155 across the 30 observational. Of the 100 that completed or were terminated, 42 (42%) have results posted.
This tab as a report to print or save as PDF → With an account.
11 of 147 have an industry lead sponsor. The 10 most frequent:
This is the only study on the registry with Winston Manimtim as lead sponsor.
Winston Manimtim has 1 study filed under Bronchopulmonary Dysplasia — fewer than ten, so there is no comparison to draw.
19 of the studies in Bronchopulmonary Dysplasia with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04278404Duke UniversityPharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS) | 2026-11 |
| NCT03797183University of Colorado, DenverGenesis Electrical Impedance Tomography (EIT): A Preliminary Study | 2026-11 |
| NCT04372953Murdoch Childrens Research InstitutePositive End-Expiratory Pressure (PEEP) Levels During Resuscitation of Preterm Infants at Birth (The POLAR Trial). | 2026-11-30 |
| NCT05568264Shirley Ryan AbilityLabEffects of a Physical Therapy Intervention on Motor Delay in Infants Admitted to a Neonatal Intensive Care Unit | 2026-12-31 |
| NCT07447739Khang NguyenCan Betamethasone Given After Birth Help Extremely Premature Babies Come Off Breathing Support Safely and Effectively? | 2027-03 |
Add all 19 to your calendar (.ics) → With an account.
Among the 147 studies in Bronchopulmonary Dysplasia with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to use forced oscillometry technique (FOT) to measure pulmonary mechanics and function in in term infants and premature infants with bronchopulmonary dysplasia (BPD)
Pulmonary function testing has been the standard of care to diagnose and evaluate response to therapy in various respiratory diseases in adults and children. There are several equipment and techniques that are FDA approved for these purposes. However, there are currently no lung function tests that are practically feasible, clinically meaningful and widely used in infants.
The forced oscillation technique (FOT) is a non-invasive method that had been used to measure respiratory mechanics. FOT employs small amplitude pressure oscillations superimposed on the normal breathing and therefore has the advantage over conventional lung function techniques that it does not require the performance of respiratory maneuvers. To date, the use of this technique is FDA approved in adults and children but remains largely experimental in infants and newborns. THORASYS has recently developed a new respiratory function test device aimed specifically at newborn and infants (0 - 2 years age group) called tremoflo N-100 ("Neo"). This new device measures lung function in only a few minutes while the newborn or infant is sleeping normally. It uses an adapted version of the Airwave Oscillometry (AOS) to calculate the impedance of the lungs and quantify airway obstruction.
Diuretics and bronchodilators are two on the most commonly used medications to ameliorate the symptoms of BPD. The benefits of these therapies have not been shown to prevent the development of BPD in a randomized control trial (RCT). More recently, there have been some evidence from pharmacogenetic studies that the variability in bronchodilator responsiveness in patients with asthma, (and possibly BPD) may lie on the gene encoding the B2-adrenergic receptor (ADRB2) as well as within the associated G-protein receptor pathway, the nitric oxide biosynthetic pathway and other novel loci identified in recent genome-wide studies. This part of the study will be hypothesis generating to try to understand the variability in bronchodilator response in infants with BPD. Normative data will be established in term neonates.
363 studies on the registry are indexed under Bronchopulmonary Dysplasia; 85 are open to participants now.
This study's enrollment of 44 is below the median of 150 across 100 observational studies indexed under Bronchopulmonary Dysplasia.
Browse Bronchopulmonary Dysplasia studies →This is the only study on the registry with Winston Manimtim as lead sponsor.
Compared within Bronchopulmonary Dysplasia, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Infant, Premature, Diseases. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Premature infants with bronchopulmonary Dysplasia who are in room air or Premature infants with BPD who are receiving low flow O2 support and able to maintain normal spO2 in Room air for brief period (up to 3 minutes) Term infants without pulmonary disease. Former preterm infants (\<32 weeks) with BPD seen prior to 2 years of age in the outpatient setting.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Preterm Cohort:
Outpatient Cohort:
Exclusion Criteria:
Non-invasive forced airway oscillometry. Normative data will be established form term neonates without pulmonary disease
Device: Non-invasive forced airway oscillometry
This non-invasive device will measure pulmonary mechanics in spontaneously breathing premature infants and term infants without pulmonary disease. Infant will be in supine position and breathing regularly. A cushioned mask will be placed on the infant's face, covering the nose and mouth. Measurements typically take less than 20 seconds and no more than 3 repetitions will be done at each time point.
Forced oscillation technique measurements
Baseline FOT measurements in premature infants with BPD and term infants without pulmonary disease.
Time frame: FOT measurement prior to bronchodilator therapy
Post-bronchodilator forced oscillation technique measurements (in subjects already receiving this therapy)
FOT measurements in premature infants with BPD following bronchodilator therapy.
Time frame: FOT measurement 30 to 60minutes following bronchodilator therapy
Plan to share: No
No publications or documents are linked to this record.
Ran from Oct 2019 to primary completion in Aug 2026, 82 months.
Of 47 non-industry observational studies under Bronchopulmonary Dysplasia, half reached primary completion within 56 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 82. This study's 82 months is above that.
Counting every sponsor, half of 49 studies reached it within 56 months; a quarter within 19 and three quarters within 82.
Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 13, 2026: start Feb 2020 → Oct 2019, primary completion Sep 2027 → Aug 2026 and completion Dec 2027 → Aug 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.